https://pharminent.com/fda-reverses-course-on-atara-pierre-fabres-twice-rejected-cell-therapy-after-prasads-exit/ 2026-05-07T15:56:11Z Pharminent en FDA reverses course on Atara, Pierre Fabre's twice-rejected cell therapy after Prasad's exit 2026-05-07T14:57:05Z Blog https://pharminent.com/angelini-inks-4-1b-catalyst-buy-to-enter-us-rare-disease-market/ 2026-05-07T15:56:15Z Pharminent en Angelini inks $4.1B Catalyst buy to enter US rare disease market 2026-05-07T14:46:04Z Blog https://pharminent.com/bayer-plans-filings-for-cardiac-amyloidosis-imaging-agent/ 2026-05-07T15:56:18Z Pharminent en Bayer plans filings for cardiac amyloidosis imaging agent 2026-05-07T12:53:11Z Blog https://pharminent.com/roche-buys-ai-powered-diagnostics-player-pathai/ 2026-05-07T15:56:20Z Pharminent en Roche buys AI-powered diagnostics player PathAI 2026-05-07T11:40:36Z Blog https://pharminent.com/daiichi-sankyo-and-waiv-partner-for-adc-biomarkers-2/ 2026-05-07T16:27:26Z Pharminent en Daiichi Sankyo and Waiv partner for ADC biomarkers 2026-05-07T09:03:01Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-may-6-2026/ 2026-05-06T23:10:14Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • May 6, 2026 2026-05-06T23:10:10Z Blog https://pharminent.com/novo-nordisk-raises-guidance-on-strong-wegovy-pill-launch/ 2026-05-06T23:02:45Z Pharminent en Novo Nordisk Raises Guidance on Strong Wegovy Pill Launch 2026-05-06T22:58:40Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-may-6-2026/ 2026-05-06T19:08:56Z Pharminent en Manufacturing Intelligence • Weekly Digest • May 6, 2026 2026-05-06T19:08:53Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-6-2026/ 2026-05-06T17:31:22Z Pharminent en Strategic News Watch • May 6, 2026 2026-05-06T17:31:19Z Blog https://pharminent.com/fda-expands-ai-capabilities-and-completes-data-platform-consolidation/ 2026-05-07T15:56:20Z Pharminent en FDA Expands AI Capabilities and Completes Data Platform Consolidation 2026-05-06T16:57:45Z Blog https://pharminent.com/bayer-to-buy-perfuse-for-up-to-2-45b-bolstering-eye-drug-pipeline/ 2026-05-07T15:56:21Z Pharminent en Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline 2026-05-06T16:02:00Z Blog https://pharminent.com/novo-hikes-guidance-on-wegovy-pills-fast-sales-start/ 2026-05-06T16:39:36Z Pharminent en Novo hikes guidance on Wegovy pill's fast sales start 2026-05-06T15:26:21Z Blog https://pharminent.com/bayer-looks-to-uphold-eylea-legacy-with-2-45bn-perfuse-buyout/ 2026-05-06T16:39:39Z Pharminent en Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout 2026-05-06T15:13:21Z Blog https://pharminent.com/lilly-inflates-us-facility-investment-spending-by-4-5bn/ 2026-05-07T15:35:47Z Pharminent en Lilly inflates US facility investment spending by $4.5bn 2026-05-06T14:53:10Z Blog https://pharminent.com/fda-launches-one-day-inspectional-assessments-to-strengthen-and-expand-oversight/ 2026-05-06T16:39:41Z Pharminent en FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight 2026-05-06T14:00:46Z Blog https://pharminent.com/novos-wegovy-pill-reaches-1m-patients-shattering-expectations-with-355m-in-sales/ 2026-05-07T15:35:50Z Pharminent en Novo's Wegovy pill reaches 1M patients, shattering expectations with $355M in sales 2026-05-06T13:54:44Z Blog https://pharminent.com/cellcentric-secures-220m-in-europes-biggest-private-biotech-fundraise-of-2026/ 2026-05-06T16:45:25Z Pharminent en CellCentric secures $220M in Europe's biggest private biotech fundraise of 2026 2026-05-06T13:39:58Z Blog https://pharminent.com/gsk-bolts-on-sirna-drug-from-chinas-siranbio-in-1bn-deal/ 2026-05-06T16:39:43Z Pharminent en GSK bolts on siRNA drug from China's SiranBio in $1bn deal 2026-05-06T11:28:24Z Blog https://pharminent.com/cellcentric-raises-220m-for-a-transformative-multiple-myeloma-medicine/ 2026-05-06T16:39:43Z Pharminent en CellCentric raises $220M for a 'transformative' multiple myeloma medicine 2026-05-06T11:00:00Z Blog https://pharminent.com/msd-concludes-terns-acquisition-to-expand-cml-pipeline/ 2026-05-06T16:39:45Z Pharminent en MSD concludes Terns acquisition to expand CML pipeline 2026-05-06T10:15:16Z Blog https://pharminent.com/msd-concludes-terns-acquisition-to-expand-cml-pipeline-2/ 2026-05-06T16:09:19Z Pharminent en MSD concludes Terns acquisition to expand CML pipeline 2026-05-06T08:47:44Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-may-5-2026/ 2026-05-05T23:15:40Z Pharminent en Oncology Intelligence Digest • May 5, 2026 2026-05-05T23:15:38Z Blog https://pharminent.com/fda-expands-market-access-authorizes-new-ends-products/ 2026-05-06T16:09:24Z Pharminent en FDA Expands Market Access, Authorizes New ENDS Products 2026-05-05T19:10:20Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-5-2026/ 2026-05-05T17:25:26Z Pharminent en Strategic News Watch • May 5, 2026 2026-05-05T17:25:24Z Blog https://pharminent.com/viridian-data-lift-prospects-for-thyroid-eye-disease-drug/ 2026-05-06T16:09:25Z Pharminent en Viridian data lift prospects for thyroid eye disease drug 2026-05-05T16:04:48Z Blog https://pharminent.com/quralis-phase-2-data-bolster-case-for-genetic-approach-to-sporadic-als/ 2026-05-05T16:22:50Z Pharminent en QurAlis' Phase 2 data bolster case for genetic approach to sporadic ALS 2026-05-05T13:55:00Z Blog https://pharminent.com/pfizer-stays-the-course-for-2026-guidance-dulling-impact-of-q1-earnings-beat/ 2026-05-05T15:48:08Z Pharminent en Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat 2026-05-05T13:33:05Z Blog https://pharminent.com/cytokinetics-heart-drug-scores-in-closely-watched-trial/ 2026-05-05T15:48:11Z Pharminent en Cytokinetics heart drug scores in closely watched trial 2026-05-05T12:38:00Z Blog https://pharminent.com/specialty-pharmacy-accreditation-dcis-exclusive-analysis-reveals-a-market-at-an-inflection-point/ 2026-05-05T15:48:13Z Pharminent en Specialty Pharmacy Accreditation: DCI's Exclusive Analysis Reveals a Market at an Inflection Point 2026-05-05T10:30:00Z Blog https://pharminent.com/lannett-lanexa-biologics-and-sunshine-lake-secure-fda-approval-for-langlara/ 2026-05-05T15:48:16Z Pharminent en Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara 2026-05-05T10:08:28Z Blog https://pharminent.com/seismic-shift-as-obesity-overtakes-cancer-for-rd-returns/ 2026-05-05T15:48:16Z Pharminent en 'Seismic shift' as obesity overtakes cancer for R&D returns 2026-05-05T09:58:57Z Blog https://pharminent.com/latus-bio-secures-97m-in-funding-to-boost-gene-therapy-access/ 2026-05-05T15:48:17Z Pharminent en Latus Bio secures $97m in funding to boost gene therapy access 2026-05-05T09:53:25Z Blog https://pharminent.com/autoimmune-disease-biotech-odyssey-sets-terms-for-225m-ipo/ 2026-05-05T15:48:18Z Pharminent en Autoimmune disease biotech Odyssey sets terms for $225m IPO 2026-05-05T08:52:32Z Blog https://pharminent.com/cytospire-hauls-in-83m-for-a-new-type-of-t-cell-engager/ 2026-05-05T15:41:43Z Pharminent en Cytospire hauls in $83M for a new type of T cell engager 2026-05-05T07:00:00Z Blog